BMO Capital Upgrades Beam Therapeutics to Outperform, Raises Price Target to $66
BMO Capital analyst Kostas Biliouris upgrades Beam Therapeutics (NASDAQ:BEAM) from Market Perform to Outperform and raises the price target from $61 to $66.
Benzinga’s Top Ratings Upgrades, Downgrades For December 13, 2022
Upgrades For Equinix Inc (NASDAQ:EQIX), Cowen & Co. upgraded the previous rating of Market Perform to Outperform. In…
Citigroup Initiates Coverage On Beam Therapeutics with Buy Rating, Announces Price Target of $62
Citigroup analyst Samantha Semenkow initiates coverage on Beam Therapeutics (NASDAQ:BEAM) with a Buy rating and announces Price Target of $62.
Unity Software, Amazon, Doximity And Other Big Gainers From Friday
U.S. stocks closed higher on Friday, with the Nasdaq Composite jumping more than 200 points. Here is the list of some big stocks recording gains in the previous session.
TreeHouse Foods, Ritchie Bros. Auctioneers, Beam Therapeutics And Some Other Big Stocks Moving Lower On Monday
U.S. stocks traded mostly higher, with the Dow Jones gaining more than 150 points on Monday. Here are some big stocks recording losses in today’s session.
SVB Leerink Maintains Outperform on Beam Therapeutics, Lowers Price Target to $81
SVB Leerink analyst Mani Foroohar maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and lowers the price target from $82 to $81.
Beam Therapeutics Q3 EPS $(1.56) Down From $(0.42) YoY, Sales $15.80M Up From $763.00K YoY
Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(1.56) per share. This is a 271.43 percent decrease over losses of $(0.42) per share from the same period last year. The company reported $15.80 million in
ON Semiconductor, Global Payments And Other Big Losers From Monday
U.S. stocks closed lower on Monday, with the Dow Jones dropping more than 100 points. Here is the list of some big stocks recording losses in the previous session.
Beam Therapeutics Touts Encouraging Preclinical Data From Gene Editing Approach For Hepatitis B Infection
Beam Therapeutics Inc (NASDAQ:BEAM) announced new preclinical data demonstrating the potential of its multiplex base editing approach to reduce hepatitis B…
Beam Therapeutics Earnings Perspective: Return On Capital Employed
Benzinga Pro data, Beam Therapeutics (NASDAQ:BEAM) reported Q2 sales of $16.65 million. Earnings fell to a loss of $71.95 million, resulting in a 3.95% decrease from last quarter.